The odd thing about a medical breakthrough is how many times it must be invented. First in a laboratory. Again in a clinical trial. Again in a factory. Then, when everybody is exhausted, it has to be invented one more time in Washington - as a bill, a regulation, a coverage decision, a reimbursement code, or a sentence an agency official can defend in a meeting.
Jeffrey J. Kimbell & Associates lives in that last reinvention. It is a Washington government-relations firm with the soul of a technical translation shop. A client may arrive with a new device, drug, diagnostic, provider service, or gene therapy. The firm's job is to identify the federal obstacle between that product and the people meant to use it, then decide whether the right instrument is Congress, FDA, CMS, an advisory panel, a public comment, a coalition, or simply a better explanation.
The company says it now represents more than 85 clients, primarily in life sciences, with 25 full-time professionals: 11 lobbyists and seven healthcare-policy experts. That is a revealing ratio. The firm does not treat policy expertise as the research department behind the rainmakers. Policy is one half of the product.
01. The product after the product
Consider a company approaching its first launch. Regulatory approval is only one gate. Will Medicare cover the technology? Which code describes it? Under which payment system will a hospital, clinic, or physician be reimbursed? Does the existing rule understand the new thing, or force it into an old category that makes no economic sense?
Kimbell's health and reimbursement group works through precisely those questions. It advises on Medicare, Medicaid, 340B, and TRICARE; helps prepare HCPCS and ICD-10-CM applications; supports companies through national coverage analyses; and works on transitional pass-through payment requests for biopharmaceuticals. For pre-commercial companies, the engagement can begin years before launch. That timing is the point. A reimbursement problem discovered after approval can be painfully close to a business-model problem.
Government affairs adds the political machinery. The firm monitors hearings and rules, drafts agency comments and testimony, coordinates meetings, works with trade associations and patient groups, and organizes tours of manufacturing plants, research facilities, hospitals, and clinical settings. The tour may sound like the softest item on the list. It may be the most human. A policymaker can ignore an abstraction. It is harder to ignore a production line, a physician using a device, or a patient describing the distance between approval and access.
“We help our clients build lasting, trusting relationships with federal officials in Washington.”Jeffrey J. Kimbell & Associates
02. The founder saw the bottleneck early
Jeff Kimbell did not arrive at this model from a generic public-affairs agency. From 1994 to 1998, he was the first executive director of the Medical Device Manufacturers Association. During his tenure, the association grew from 25 companies to 130 and participated in the push to overhaul FDA's product-approval process. In 1998, Kimbell left to start the firm that bears his name.
The origin matters because it explains the firm's bias. A small medical-device company does not experience Washington as a grand ideological debate. It experiences Washington as a queue, a deadline, a classification, and an official definition written before its technology existed. Kimbell's firm was built to work at that resolution.
It has since widened the aperture. Government affairs sits beside communications and public affairs, corporate PAC services, reimbursement policy, and a health-technology and artificial-intelligence practice. The AI group tracks policy around clinical decision support, software as a medical device, AI in drug development and clinical trials, interoperability, privacy, and cybersecurity. This is less a pivot away from the original thesis than proof of it: the technology changes faster than the rulebook, so somebody must translate in both directions.
03. What the retainer buys
The business model is the familiar Washington retainer, made visible in federal disclosure forms. The firm does not publish a price list, and public lobbying numbers do not capture all of its consulting and communications work. But filings show the shape of the market: individual client engagements are often reported in rounded quarterly amounts such as $10,000, $20,000, or $30,000. A Bloomberg Government industry report put the firm's 2024 federal lobbying revenue at roughly $4.2 million.
What the client buys is not a guaranteed result. It buys sustained attention to a process most operating teams encounter only episodically. Kimbell's people know the calendars, the vocabulary, the committees, and the difference between a coding problem and a coverage problem. They also package the case: technical memo, political message, executive preparation, stakeholder coalition, public narrative.
That integrated menu is the competitive argument. A law firm can interpret the statute. A communications agency can sharpen the story. A lobbying shop can make the meeting. An in-house government-affairs team can carry institutional memory. Kimbell & Associates tries to combine enough of each discipline that the client does not have to keep translating the translator.
04. What fails first
In regulated markets, the first failure is often not access. It is translation. The engineer explains the mechanism. The reimbursement specialist explains the code. The executive explains the market. The patient explains the need. Each is correct, but the policymaker hears four different products.
The firm's method is to compress those truths into one actionable claim. Its communications practice develops policy narratives and advocacy campaigns. Its policy staff tests the claim against the actual rule. Its government-affairs staff carries it to the people with authority. Its stakeholder work recruits credible voices that are not the company itself. The sequence is copyable even without a Washington firm.
Write down the exact decision you need. “Awareness” is not a decision; a code, rule, vote, or meeting is.
Map who possesses legal authority, who supplies technical advice, and who can delay the timetable.
Start before launch. Policy constraints found early can still influence evidence plans and commercial strategy.
Let the decision-maker see the work: a facility, a procedure, a patient journey, or a clean economic model.
The firm also supplies a small cultural clue. Its anniversary account of an annual offsite included skiing, fly-fishing, a talk from an Olympian, music from an employee's band, and repeated elk burgers. “These adventures make us better,” the company wrote. That is unusually specific corporate prose, and it reveals a boutique that sells continuity as much as cleverness. Clients retain people, not a platform. A team that wants to remain together has commercial value.
05. What access cannot buy
There are boundaries. Advocacy cannot manufacture clinical evidence. It cannot give an agency authority Congress withheld. It cannot make a missed coding deadline disappear, or promise a vote, coverage decision, or payment level. The firm's strongest fit is a life-sciences organization with a specific federal problem, credible technical support, and enough runway to work through a slow public process.
A precise federal ask plus credible evidence can become a strategy. A vague desire for influence, a weak evidentiary record, or a problem governed mainly by states or foreign regulators requires a different instrument.
That makes Kimbell & Associates easier to understand than the word “lobbying” suggests. The firm occupies the narrow space where product strategy meets public law. It helps a company explain why a new thing deserves a new pathway, why an old definition no longer fits, and why the consequence of administrative friction eventually lands on a patient.
The best summary is also the least glamorous. Somewhere between the breakthrough and the bedside sits a form. Somewhere behind the form sits a rule. Somewhere behind the rule sits a room full of people who need to understand what will happen if they change it. Kimbell & Associates has spent nearly three decades learning how to enter that room prepared.